Summary:
The purpose of this research study is to see if the drug being tested, IMG-007, is safe and if it reduces inflammation and other signs and symptoms of AD, also known as eczema. In addition, the study will see how your body responds to and uses IMG-007 and how IMG-007 works in your body.
Qualified Participants Must:
• Aged ≥ 18 and < 75 years
•
Poor response to topical treatments
•
Diagnosed with Atopic dermatitis or eczema
•
Be willing to come to 19 clinic visits over 72 weeks